rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GTBP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      GT Biopharma Reports Third Quarter 2026 Financial Results
      Nov 16Yahoo FinanceGTBP
      GT Biopharma Explores A New Combination Approach For Pancreatic Cancer

      This biotech stock recently released some pleasing findings from its recent cancer treatment study.

      Nov 10Yahoo FinanceGTBP
      GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting
      Nov 9Yahoo FinanceGTBP
      GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

      SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ. Oral Presentation Details

      Oct 26Yahoo FinanceGTBP
      GT Biopharma Regains Nasdaq Minimum Bid Compliance

      Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailGTBP
      GT Biopharma Expands Series M Preferred Financing Agreement

      Tipranks Press Release.

      Sep 22The Globe and MailGTBP
      EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
      Sep 16Yahoo FinanceGTBP
      GT Biopharma announces $7.45 million private placement of preferred stock and warrants
      Sep 15Investing.comGTBP
      GT Biopharma receives FDA clearance for myeloma trial
      Sep 15Investing.comGTBP
      GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

      FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026 Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway

      Sep 15Yahoo FinanceGTBP
      EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

      GT Biopharma, Inc. (NASDAQ:GTBP) on Tuesday secured IND clearance from the U.S. Food and Drug Administration (FDA) to evaluate its novel therapeutic candidate, GTB-5550, in treating multiple myeloma. Multiple myeloma is a rare type of blood cancer that develops in the plasma cells, which are a type of white blood cell found in the bone marrow. The trial initiation is contingent upon timing and receipt of non-dilutive grant funding. Cash balance as of September 15 is approximately $11 million, an

      Sep 15Yahoo FinanceGTBP
      GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026

      SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time. The webinar will feature Michael Breen, Executive Chairman a

      Sep 11Yahoo FinanceGTBP

      This is the newest page. Registered accounts read further back.